Whether more specific antioxidant agents such as the TXNIP inhibitor, SRI-37330, will be efficacious in treating T2D remains to be determined (53, 56), but our studies encourage the continued exploration into antioxidant pathways that may be utilized to promote β cell health and function. Here, TXNIP is linked to type 2 diabetes mellitus.